Searched for
VILDAGLIPTIN
Delhi High Court seeks response from govt, NPPA on Glenmark's pleaDelhi High Court hears Glenmark Pharma's petition against NPPA's pricing order for anti-diabetic drugs, claiming arbitrary pricing and seek...- Pricing authority caps rates of key diabetes drugsIndia’s drug pricing authority has fixed prices of two key anti diabetes drugs-Sitagliptin-Metformin combination and Linagliptin-metformin ...
- Eris Lifesciences scouting for acquisitions to diversify bizThrough acquisition of Strides domestic formulations portfolio in 2017, Eris Lifesciences got a toehold in the neurology and psychiatry seg...
- Generics of MSD diabetes pill set to flood market as patent expiresAccording to market research firm AIOCD, at least 50 Indian drug makers are jumping into the fray with around 100 generic versions of the p...
- Eris Lifesciences Q4 Results: Net profit rises 17% to Rs 80 croreOn the outlook, Eris Lifesciences said it has an exciting pipeline of 'patent expiration' opportunities coming up in the cardiometabolic se...
- Glenmark launches unique fixed dose combination drug for diabetesThe Mumbai based drug firm said it has introduced fixed dose combination (FDC) of its novel, patent protected Sodium Glucose Co-Transporter...
- Cadila Healthcare Q4 results: Net profit declines 15% at Rs 392 croreNet profit of the company for the fiscal ended March this year was Rs 1,176.6 crore as against Rs 1,848.8 crore for the previous fiscal, Ca...
- Torrent Pharmaceuticals puts faith in local market, to focus on new drug launchesThe Ahmedabad-based company, part of the Rs 14,000-crore Torrent Group, is the only domestic pharma co that has invested nearly $1 bn in lo...
- After Market: Kolte-Patil surges 14%; metals shine; Pharma, realty declineIndia VIX, the index of volatility in the markets, slumped 6.5 per cent to 12.54.
- Cipla shares rise after Vysov anti-diabetic drug acquisitionCipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin), the ...
- USV in talks with Novartis to buy Jalra Trademark for Rs. 200 CroreMumbai-based drugmaker USV Pvt Ltd is in advanced discussions to acquire the trademark for antidiabetes drug Jalra from Novartis for a deal...
- Citigroup maintains buy on Eris Lifesciences, raises target price to Rs 750The brokerage has raised FY21 and FY22 estimated EPS by 2.5% and 3% respectively.
- Mega diabetes drug to be cheaper soonWith Novartis losing patent protection for Vildagliptin in December, the cost of therapy is expected to reduce by over 50%.
- Cipla to market Novartis, and J&J’s products, while Alkem partners Dong A of South KoreaAlkem is bringing in a fresh brand. Evogliptin has been approved in South Korea and the company is waiting for an approval from the USFDA a...
- 4 pharma companies under CCI scanner over price-fixingNovartis, Abbott among cos served notice for alleged cartelisation in diabetic drug.
- CCI starts probe on alleged price fixing of key anti diabetic drugsEmcure also did not respond to an email query as of press time while USV remained unreachable for a comment.
- Anti-diabetic drug cartel issue reaches CCI, Health MinistryCCI had been informed about the cartelisation allegations in a letter dated Feb 27, ET reported earlier. At that time, Novartis had denied ...
- NPPA to look into diabetes drug price-fixing allegationsVildagliptin is a proprietary drug of Novartis sold under the brand Galvus and comes under a new class of anti-diabetic drugs known as DPP ...
- India rejects compulsory license application of Lee Pharma against AstraZeneca’s SaxagliptinThe Indian Patent Office has rejected the application of Lee Pharma for a compulsory license on AstraZeneca’s anti-diabetes drug saxaglipti...
- NeoBiocon partners Novartis to launch diabetes drugs in UAENeoBiocon has received approvals from the Ministry of Health-UAE for marketing Jalra and Jalra-M in the country and the launch is scheduled...
Load More
